We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

LumiQuick Diagnostics

LumiQuick Diagnostics Inc. develops, manufactures and markets high quality point of care tests and other immunoassay ... read more Featured Products: More products

Download Mobile App





LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio

By LabMedica International staff writers
Posted on 28 Jul 2026

LumiQuick Diagnostics, Inc. More...

(Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies bring products to the U.S. market. Building on the successful integration of AOXRE, LumiQuick is positioned to support oxidative stress research and specialty diagnostic technologies.

Beyond supplying products, the expanded offering includes original equipment manufacturer (OEM), private-label, and contract manufacturing services, along with strategic commercialization support for the United States. Together, these capabilities are designed to support partners from early development through market entry.

The service scope spans product development, design transfer, manufacturing scale‑up, and product assembly and packaging. Operational capabilities include reagent dispensing and packaging and custom diagnostic solutions across lateral flow immunoassays, rapid diagnostic tests, and ELISA development and manufacturing. 

The company's expertise also includes recombinant proteins, antibodies, biomarker assays, and reagent formulation, providing a single‑source pathway from concept through commercialization. Regulatory services include U.S. Food and Drug Administration (FDA) 510(k) submission support.

LumiQuick is seeking collaborations with biotechnology companies, diagnostic developers, research organizations, and international manufacturers aiming to establish or expand their U.S. presence with an experienced commercial and manufacturing partner. The team will be available at the ADLM Clinical Lab Expo 2026, Booth #1156, to discuss the expanding AOXRE portfolio, new product innovations, OEM and private‑label options, contract manufacturing, FDA 510(k) support, and commercialization partnerships.

The initiative underscores a commitment to advancing oxidative stress research and specialty diagnostic technologies through continued product innovation, expanded manufacturing capabilities, and strategic industry partnerships.

“Our goal is to become more than a manufacturer,” said Talita Franco, Business Development & Marketing Director at LumiQuick Diagnostics. “We are committed to helping innovative companies transform scientific discoveries into commercially successful products by combining technical expertise, manufacturing excellence, regulatory guidance, and market development support.”


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.